Follow Us
https://www.thebody.com/category/tivicay-dolutegravir/tag/news

The Latest

Dovato Is a Newly Approved Two-Drug HIV Regimen. Do Fewer Drugs Mean a Lower-Cost HIV Treatment? Img

Dovato Is a Newly Approved Two-Drug HIV Regimen. Do Fewer Drugs Mean a Lower-Cost HIV Treatment?

Advocates say the price is a step in the right direction. But does it go far enough?

Q&A on Dolutegravir Use in Women of Childbearing Age Img

Q&A on Dolutegravir Use in Women of Childbearing Age

Questions and answers on potential risk of neural tube defects in infants born to women who were taking dolutegravir (DTG) at the time of conception.

Promo Image

Taking the Shine Off Tivicay

Tivicay is a mainstay of HIV treatment and the focus of simplified treatment studies due to its power and high drug resistance barrier; however, side effects concerns have recently been raised.

Two New HIV Drugs Win Recommendation as Official First-Line Treatment Options Img

Two New HIV Drugs Win Recommendation as Official First-Line Treatment Options

Stribild, a once-daily, single-pill regimen, and Tivicay, a recently approved integrase inhibitor, are now officially on the list of "preferred" HIV medications in official U.S. HIV treatment guidelines.